Innovating Works

Leyden Delta

Desconocido
CRESTAR: Pharmacogenomic biomarkers as clinical decision making tools for clozapine treatment of schizophreni... LEYDEN DELTA BV participó en un FP7: Treatment resistant schizophrenia (TRS) is the most disabling of all psychiatric illnesses, affecting about 1/3 of patients (~1 million Euro...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.